PDF factsheet

Z

Niacin for cardiovascular prevention clinical trials results

niacin versus control
VA drugs, 1968	niacin versus		double blind Follow-up duration: 3.2 years
niacin versus ezetimibe
ARBITER 6-HALTS (niacin vs ezetimibe), 2009 NCT00397657	extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) versus ezetimibe 10 mg/d (LDL-focused strategy)	patients with known coronary or vascular disease or coronary risk equivalents	open Follow-up duration: 14 months US
niacin versus placebo
CDP niacin, 1975	niacin 3 mg/d versus placebo	Hommes, de 30 à 64 ans	double blind Follow-up duration: 6.2 years
niacin versus placebo (on top statin)
AIM-HIGH, 2011 NCT00120289	high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) versus placebo	patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol	double blind Follow-up duration: 32 months US, Canada
HPS 2-Thrive, NCT00461630	2 g of extended-release niacin and 40 mg of laropiprant versus placebo	patients with vascular disease	double blind Follow-up duration: 3.9y (median) UK, Scandinavia, China
Oxford Niaspan Study, 2009 NCT00232531	niacin 2g daily (added to statin therapy) versus placebo (statins alone)	patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis	double blind Follow-up duration: 1 year USA
ARBITER 2, 2009	long-acting niacin target dose of 1 g/day (added to statin therapy) versus placebo	patients with known coronary artery disease and well controlled on statin therapy	double blind Follow-up duration: 1 y USA
HATS, 2001	simvastatin plus niacin versus placebo	patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels	double blind Follow-up duration: 3 y USA, Canada

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags